Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBITDA Margin (2020 - 2026)

Insight Molecular Diagnostics' EBITDA Margin history spans 6 years, with the latest figure at 2057.51% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 20541.0% to 2057.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 1260.76%, a 198437.0% increase, with the full-year FY2025 number at 1260.76%, up 198437.0% from a year prior.
  • EBITDA Margin hit 2057.51% in Q4 2025 for Insight Molecular Diagnostics, up from 4249.23% in the prior quarter.
  • Over the last five years, EBITDA Margin for IMDX hit a ceiling of 1969.7% in Q1 2023 and a floor of 11752.17% in Q3 2024.
  • Historically, EBITDA Margin has averaged 2554.23% across 5 years, with a median of 1845.68% in 2025.
  • Biggest five-year swings in EBITDA Margin: soared 5168307bps in 2021 and later tumbled -1023399bps in 2024.
  • Tracing IMDX's EBITDA Margin over 5 years: stood at 994.15% in 2021, then crashed by -328bps to 4251.09% in 2022, then fell by -21bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then rose by 9bps to 2057.51% in 2025.
  • Business Quant data shows EBITDA Margin for IMDX at 2057.51% in Q4 2025, 4249.23% in Q3 2025, and 1900.0% in Q2 2025.